Kodo Okada

The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemia

Mitsuru Segawa, Yoshihiro Hirata, Shizuyoshi Fujimori et al. · Metabolism · 1988 · 38 citations

Medicine, Biochemistry, Endocrinology +17

Effect of KCD‐232, a new hypolipidemic agent, on serum lipoprotein changes in hepatoma‐bearing rats

Tsutomu Irikura, K. Takagi, Kodo Okada et al. · Lipids · 1985 · 29 citations

Life Sciences, Biochemistry, Pharmacology +17

Effect of 4-(4′-chlorobenzyloxy)benzyl nicotinate (KCD-232) on triglyceride and fatty acid metabolism in rats

Kazumi Yagasaki, Kodo Okada, Toshiro Mochizuki et al. · Biochemical Pharmacology · 1984 · 27 citations

Life Sciences, Biochemistry, Pharmacology +14

Relation of Na+, K+-ATPase to delayed motor nerve conduction velocity: Effect of aldose reductase inhibitor, ADN-138, on Na+, K+-ATPase activity

Yoshihiro Hirata, Kodo Okada · Metabolism · 1990 · 22 citations

Life Sciences, Biochemistry, Neuroscience +16

Effect of a new aldose reductase inhibitor, 8′-chloro-2′,3′-dihydrospiro [pyrrolidine-3,6′(5′H)-pyrrolo[1,2,3,-de] [1,4]bezoxazine]-2,5,5′-trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats

Yoshihiro Hirata, Shizuyoshi Fujimori, Kodo Okada · Metabolism · 1988 · 19 citations

Medicine, Neuroscience, Pharmacology +11